Saint Louis University School of Medicine faculty in hematology, oncology, and cellular therapy are committed to leadership in clinical research programs. Also as faculty of SSM Health Saint Louis University Hospital, our staff regularly conducts clinical trials of new medicines and technologies. The following studies are now seeking participants.
Studies
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ECOG-ACRIN/ EA4151 - Sagun Goyal, M.D.
A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs. maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission.
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer
AstraZeneca/PACIFIC4 - Jeevin Shahi, M.D.
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
Just-in-Time: Evaluating a Decision-based Algorithm for Plerixafor Usage in Stem Cell Mobilization in an Outpatient Transplant Center
Alexander Babic, M.D., Ph.D.
A study to evaluate stem cell collection times for patients seen at the Outpatient Bone Marrow Transplant Center at SSM Health Saint Louis University Hospital.
Reaching Rural Cancer Survivors who Smoke Using Test-Based Cessation Interventions
Alliance/A211901 - John Dombrowski, M.D., Ph.D.
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke to quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Randomized Phase II/III Trial Of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection For Early-Stage Oral Cavity Cancer
NRG/HN006 - Sean Massa, M.D.
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.
A Multicenter, Open-label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177 Lu-PSMA-I&T vs. Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Curium/Eclipse - Razi Muzaffar, D.O.
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
64Cu-SAR-BBN Positron Emission Tomorgraphy: A Phase 2 Study of Participants with PSMA-negative Biochemical Recurrence of Prostate Cancer
Clarity Pharmeceuticals, Ltd/SABRE - Medhat Osman, M.D., Ph.D.
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.
A Phase I/1Ia, First-in-Human, Multicenter Dose Escalation and Dose Expansion Study of {203 212Pb} VMT01 Receptor-targeted, Image-guided Alpha-particle Therapy in Patients with Previously Treated Unresectable or Metastatic Melanoma
Viewpoint Molecular Targeting - Medhat Osman, M.D., Ph.D.
In this first-in-human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma.
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
NRG/GU010 - Jeevin Shahi, M.D.
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness.
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (TELiMET)
Abbvie/M18-868 - Maurice Willis, M.D.
The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated.
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Abbvie/M20-621 - Nabeel Rajeh, M.D.
The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL).
Phase I/II dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as a single agent or in combination in advanced solid tumors
Merus/MCLA-158-CL01- Maurice Willis, M.D.
Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). **Currently only recruiting to metastatic colorectal cancer arm.**
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
ECOG-ACRIN/EA3191 - John Dombrowski, M.D.
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary).